Quantum dot-based quantitative immunofluorescence detection and spectrum analysis of epidermal growth factor receptor in breast cancer tissue arrays
Xue-Qin Yang1,2, Chuang Chen1, Chun-Wei Peng1, Jin-Xuan Hou1, Shao-Ping Liu1, Chu-Bo Qi3, Yi-Ping Gong4, Xiao-Bo Zhu5, Dai-Wen Pang6, Yan Li1
1Department of Oncology, Zhongnan Hospital of Wuhan University, Hubei Key Laboratory on Tumor Biological Behaviors and Hubei Cancer Clinical Study Center, Wuhan; 2Medical School of Jingchu University of Technology, Jingmen; 3Department of Pathology; 4Department of Breast Surgery, Hubei Cancer Hospital, Wuhan; 5Wuhan Jiayuan Quantum Dots Co Ltd and Wuhan Tumor Nanometer Diagnosis Engineering Research Center, Wuhan; 6Key Laboratory of Analytical Chemistry for Biology and Medicine, College of Chemistry and Molecular Sciences, and State Key Laboratory of Virology, Wuhan University, Wuhan, People's Republic of China
Background: The epidermal growth factor receptor (EGFR) is a promising therapeutic target in cancer, but its clinical value in breast cancer remains controversial. Our previous studies have found that quantitative analysis of biomarkers with quantum dot-based nanotechnology had better detection performance than conventional immunohistochemistry. The present study was undertaken to investigate the prognostic value of EGFR in breast cancer using quantum dot-based quantitative spectral analysis.
Methods: EGFR expression in 65 breast cancer specimens was detected by immunohistochemistry and quantum dot-immunohistochemistry, and comparisons were made between the two methods. EGFR expression in tissue microarrays of 240 breast cancer patients was then detected by quantum dot-immunohistochemistry and spectral analysis. The prognostic value of EGFR immunofluorescence area (EGFR area) for five-year recurrence-free survival was investigated.
Results: The same antigen localization, high correlation of staining rates (r = 0.914), and high agreement of measurement (κ= 0.848) of EGFR expression in breast cancer were found by quantum dot-immunohistochemistry and immunohistochemistry. The EGFR area showed significant differences by tumor grade, lymph node status, HER2 status, and hormone receptor status (all P < 0.05). Patients in the large EGFR area (≥30.51) group had a significantly higher five-year recurrence rate (47.2% versus 27.4%, P = 0.002) and worse five-year recurrence-free survival (log-rank test, P = 0.0015) than those in the small EGFR area (<30.51) group. In the subgroups, EGFR area was an independent prognosticator in the HER2-positive and lymph node-positive subgroups.
Conclusion: Quantum dot-based quantitative detection demonstrates the prognostic value of EGFR area in the HER2-positive and lymph node-positive subgroups of invasive breast cancer.
Keywords: quantum dots, breast cancer, epidermal growth factor receptor, quantitative analysis, recurrence-free survival, prognosis
This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.Download Article [PDF] View Full Text [HTML][Machine readable]